Equillium, Inc. (EQ): Total Liabilities
$3.29M
As of 2025-12-31
$2.65M
As of 2026-06-30
-58.6%
3-year compound annual growth
-26.7%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.29M | -49.7% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $6.54M | -76.6% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $27.96M | -39.9% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $46.48M | +145.9% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $18.90M | +21.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $15.57M | +13.8% | 2022-03-23, Balance as of period end |
| 2019-12-31 | $13.69M | +514.5% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $2.23M | -76.3% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $9.40M | n/a | 2019-03-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Equillium, Inc. (EQ) | 2025-12-31 | $3.29M | -49.7% |
| Nuvectis Pharma, Inc. (NVCT) | 2025-12-31 | $13.30M | +49.5% |
| Tvardi Therapeutics, Inc. (TVRD) | 2025-12-31 | $11.13M | -72.7% |
| Valion Bio, Inc. (VBIO) | 2025-12-31 | $7.44M | n/m |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $29.63M | +5.4% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $8.26M | +15.7% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $21.24M | -19.4% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $2.40M | -83.8% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $7.04M | -0.3% |
Compare EQ, NVCT, TVRD, VBIO side by side · Screen every company in Pharmaceutical Preparations ↗